Identification of Thiazolo[5,4-]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance.

Cancers (Basel)

KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.

Published: December 2022

c-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4-]pyridine derivatives and performed SAR studies. We observed that, among these substances, is capable of inhibiting significantly c-KIT and suppressing substantially proliferation of GIST-T1 cancer cells. It is of note that is potent against a c-KIT V560G/D816V double mutant resistant to imatinib. Compared with sunitinib, possesses higher differential cytotoxicity on c-KIT D816V Ba/F3 cells relative to parental Ba/F3 cells. In addition, kinase panel profiling reveals that has reasonable kinase selectivity. It was found that remarkably attenuates proliferation of cancer cells via blockade of c-KIT downstream signaling, and induction of apoptosis and cell cycle arrest. Furthermore, notably suppresses migration and invasion, as well as anchorage-independent growth of GIST-T1 cells. This study provides useful SAR information for the design of novel c-KIT inhibitors overcoming imatinib-resistance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817970PMC
http://dx.doi.org/10.3390/cancers15010143DOI Listing

Publication Analysis

Top Keywords

c-kit inhibitors
12
thiazolo[54-]pyridine derivatives
8
c-kit
8
inhibitors overcoming
8
overcoming imatinib
8
imatinib resistance
8
novel c-kit
8
cancer cells
8
ba/f3 cells
8
cells
5

Similar Publications

Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against -mutant melanoma.

Bioact Mater

April 2025

Wellman Center for Photomedicine and Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Cancer nanovaccines hold the promise for personalization, precision, and pliability by integrating all the elements essential for effective immune stimulation. An effective immune response requires communication and interplay between antigen-presenting cells (APCs), tumor cells, and immune cells to stimulate, extend, and differentiate antigen-specific and non-specific anti-tumor immune cells. The versatility of nanomedicine can be adapted to deliver both immunoadjuvant payloads and antigens from the key players in immunity (i.

View Article and Find Full Text PDF

IL-7 secreted by keratinocytes induces melanogenesis via c-kit/MAPK signaling pathway in Melan-a melanocytes.

Arch Dermatol Res

January 2025

Department of Genetics & Biotechnology, Graduate School of Biotechnology, College of Life Sciences, Kyung Hee University, Youngin, 17104, Republic of Korea.

Abnormal melanin synthesis within melanocytes can result in pigmentary skin disorders. Although pigmentation alterations associated with inflammation are frequently observed, the precise reason for this clinical observation is still unknown. More specifically, although many cytokines are known to be critical for inflammatory skin processes, it is unclear how they affect epidermal melanocyte function.

View Article and Find Full Text PDF

High levels of histone acetylation modifications promote the formation of PGCs.

Poult Sci

January 2025

College of Animal Science and Technology, Yangzhou University, Jiangsu Province Key Laboratory of Animal Breeding and Molecular Design, Yangzhou 225009 Jiangsu, PR China; Joint International Research Laboratory of Agriculture and Agri-Product Safety of Ministry of Education of China, Yangzhou University, Yangzhou 225009 Jiangsu, PR China. Electronic address:

This study investigates the role of histone acetylation in the differentiation of chicken embryonic stem cells (ESCs) into primordial germ cells (PGCs). Transcriptomic sequencing was used to analyze differentially expressed genes during this differentiation process, with functional annotation identifying genes associated with histone acetylation. To explore the role of acetylation, acetate and an acetyltransferase inhibitor (ANAC) were added to the ESCs induction medium.

View Article and Find Full Text PDF
Article Synopsis
  • Ovarian cancer is the most deadly gynecological cancer, with current chemotherapy often ineffective due to drug resistance, especially in advanced stages.
  • A new treatment using a nanoformulation called Bola/IM targets ovarian cancer stem cells (CSCs) more effectively than imatinib alone, utilizing a specific mechanism to inhibit cancer growth and spread.
  • The Bola/IM formulation shows promising results in lab models and enhances the effectiveness of cisplatin, making it a strong candidate for improving treatment for metastatic ovarian cancer.
View Article and Find Full Text PDF

Folic Acid-Modified Milk Exosomes Delivering c-Kit siRNA Overcome EGFR-TKIs Resistance in Lung Cancer by Suppressing mTOR Signaling and Stemness.

Int J Biol Sci

January 2025

Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, 610041.

Article Synopsis
  • The study addresses a common issue in lung cancer treatment, where patients develop resistance to EGFR-TKIs like gefitinib, leading to worse outcomes.
  • The researchers developed a novel therapy using folic acid-modified milk exosomes loaded with c-kit siRNA (FA-mExo-siRNA-c-kit) to counteract this resistance by targeting the c-kit gene, which is linked to stemness traits in cancer cells.
  • Results showed that this approach not only reduced c-kit expression and stemness characteristics but also slowed tumor growth and improved survival in experimental models, highlighting its potential as a new treatment strategy for resistant lung cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!